MILLENIUM CONFERENCE ON NUCLEIC ACID THERAPEUTICS

核酸治疗千年会议

• 批准号: 6023979
• 负责人: ERIC WICKSTROM
• 金额: $ 0.55万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6023979
• 关键词: chronic disease /disorder; drug /agent; gene therapy; meeting /conference /symposium; microorganism disease chemotherapy; neoplasm /cancer chemotherapy; oligonucleotides; polynucleotides; transfection /expression vector; travel

A broad international research effort to develop nucleic acid analogs and vectors for treatment of cancers, chronic diseases, and microorganisms has reached the stage of clinical trials and the first FDA approval of a DNA drug. Great progress has occurred since the last Conference on Nucleic Acid Therapeutics in 1991. The 2000 meeting will provide a forum whereby the most recent developments in preparing gene specific drugs and vectors, and applying those agents in preclinical and clinical trials will be shared among scientists, clinicians, and regulators from around the world. Support is requested from NIH for a portion of the travel expenses of the 24 invited speakers. Funds for other expenses will be raised from interested vendors and pharmaceutical firms, as well as the International Union of Biochemistry and Molecular Biology. The conference follows the design of a Gordon Research Conference. Up to 300 participants will arrive on a Saturday, then attend six 20-minute talks during each morning and evening session on Sunday, Monday, and Tuesday. Oligonucleotide Derivatives, Diagnostic Oligonucleotide Chips, Mechanisms and Pharmacology, Preclinical Trials, Gene Therapy Vectors, and Clinical Trials will be discussed. Poster sessions will be held in the afternoons, leaving participants free to discuss mutual research interests and develop new projects. The cost of food is included in the registration fee. Most participants will stay at the conference hotel, and eat all their meals together. This meeting design encourages the maximum possible interaction of participants. The conference design, as well as the modest registration fee, hotel costs, and airfare will maximize the feasibility of attendance by young faculty, postdoctoral fellows, and graduate students. Speakers will be directed to present hard data from recent experiments, as opposed to illustrative presentations intended to persuade investors. There will be no special luncheons for speakers, no outside conference management firm, and no expensive banquet. Some of the funds raised will be utilized to make possible participation by promising young investigators who are unable to identify sufficient support for travel expenses. Through this design, the 2000 conference will stimulate new collaborations and potentiate new ideas by new and experienced investigators.

一项广泛的国际研究努力，开发用于治疗癌症、慢性疾病和微生物的核酸类似物和载体，已经达到临床试验阶段，并首次获得FDA批准的DNA药物。 自1991年上一届核酸治疗学会议以来，核酸治疗学取得了很大进展。 2000年的会议将提供一个论坛，使来自世界各地的科学家、临床医生和管理人员能够分享在制备基因特异性药物和载体以及在临床前和临床试验中应用这些药物方面的最新进展。 请NIH支持24名受邀演讲者的部分差旅费。 其他费用的资金将从感兴趣的供应商和制药公司以及国际生物化学和分子生物学联合会筹集。会议遵循戈登研究会议的设计。 多达300名与会者将在星期六抵达，然后在星期日、星期一和星期二的每个上午和晚上参加六次20分钟的会谈。 寡核苷酸衍生物，诊断寡核苷酸芯片，机制和药理学，临床前试验，基因治疗载体和临床试验将被讨论。 海报会议将在下午举行，让参与者自由讨论共同的研究兴趣和开发新的项目。 食物的费用包含在注册费中。 大多数与会者将住在会议酒店，并一起吃饭。 这种会议设计鼓励与会者尽可能多地进行互动。会议设计，以及适度的注册费，酒店费用和机票将最大限度地提高年轻教师，博士后研究员和研究生出席的可行性。 演讲者将被引导展示最近实验的硬数据，而不是旨在说服投资者的说明性演示。 没有为演讲者准备的特别午餐会，没有外部会议管理公司，也没有昂贵的宴会。 筹集到的部分资金将用于使有前途的年轻调查员能够参加，因为他们无法找到足够的旅费支助。 通过这一设计，2000年会议将促进新的合作，并加强新的和有经验的调查人员的新想法。